Browse CEACAM1

Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Single-pass type I membrane protein Lateral cell membrane Apical cell membrane Basal cell membrane Cell junction Cell junction, adherens junction Note=Canalicular domain of hepatocyte plasma membranes. Found as a mixture of monomer, dimer and oligomer in the plasma membrane. Occurs predominantly as cis-dimers and/or small cis-oligomers in the cell junction regions. Found as dimer in the solution. Predominantly localized to the lateral cell membranes. ; SUBCELLULAR LOCATION: Isoform 2: Secreted ; SUBCELLULAR LOCATION: Isoform 3: Secreted ; SUBCELLULAR LOCATION: Isoform 4: Secreted ; SUBCELLULAR LOCATION: Isoform 5: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 6: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 7: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 8: Cell membrane Single-pass type I membrane protein Cytoplasmic vesicle, secretory vesicle membrane Lateral cell membrane Apical cell membrane Basal cell membrane Cell junction Cell junction, adherens junction Note=Predominantly localized to the lateral cell membranes. Found as a mixture of monomer, dimer and oligomer in the plasma membrane. Occurs predominantly as cis-dimers and/or small cis-oligomers in the cell junction regions (By similarity). Co-localizes with ANXA2 in secretory vesicles and with S100A10/p11 at the plasma membrane (PubMed:14522961). ; SUBCELLULAR LOCATION: Cell projection, microvillus membrane Single-pass type I membrane protein Apical cell membrane Single-pass type I membrane protein Note=Colocalizes with CEACAM20 at the apical brush border of intestinal cells.
Domain PF00047 Immunoglobulin domain
PF13895 Immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Isoform 1: Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Plays a role as coinhibitory receptor in immune response, insulin action and functions also as an activator during angiogenesis (PubMed:18424730, PubMed:23696226, PubMed:25363763). Its coinhibitory receptor function is phosphorylation- and PTPN6 -dependent, which in turn, suppress signal transduction of associated receptors by dephosphorylation of their downstream effectors. Plays a role in immune response, of T cells, natural killer (NK) and neutrophils (PubMed:18424730, PubMed:23696226). Upon TCR/CD3 complex stimulation, inhibits TCR-mediated cytotoxicity by blocking granule exocytosis by mediating homophilic binding to adjacent cells, allowing interaction with and phosphorylation by LCK and interaction with the TCR/CD3 complex which recruits PTPN6 resulting in dephosphorylation of CD247 and ZAP70 (PubMed:18424730). Also inhibits T cell proliferation and cytokine production through inhibition of JNK cascade and plays a crucial role in regulating autoimmunity and anti-tumor immunity by inhibiting T cell through its interaction with HAVCR2 (PubMed:25363763). Upon natural killer (NK) cells activation, inhibit KLRK1-mediated cytolysis of CEACAM1-bearing tumor cells by trans-homophilic interactions with CEACAM1 on the target cell and lead to cis-interaction between CEACAM1 and KLRK1, allowing PTPN6 recruitment and then VAV1 dephosphorylation (PubMed:23696226). Upon neutrophils activation negatively regulates IL1B production by recruiting PTPN6 to a SYK-TLR4-CEACAM1 complex, that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome. Downregulates neutrophil production by acting as a coinhibitory receptor for CSF3R by downregulating the CSF3R-STAT3 pathway through recruitment of PTPN6 that dephosphorylates CSF3R (By similarity). Also regulates insulin action by promoting INS clearance and regulating lipogenesis in liver through regulating insulin signaling (By similarity). Upon INS stimulation, undergoes phosphorylation by INSR leading to INS clearance by increasing receptor-mediated insulin endocytosis. This inernalization promotes interaction with FASN leading to receptor-mediated insulin degradation and to reduction of FASN activity leading to negative regulation of fatty acid synthesis. INSR-mediated phosphorylation also provokes a down-regulation of cell proliferation through SHC1 interaction resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 and phosphatidylinositol 3-kinase pathways (By similarity). Functions as activator in angiogenesis by promoting blood vessel remodeling through endothelial cell differentiation and migration and in arteriogenesis by increasing the number of collateral arteries and collateral vessel calibers after ischemia. Also regulates vascular permeability through the VEGFR2 signaling pathway resulting in control of nitric oxide production (By similarity). Downregulates cell growth in response to EGF through its interaction with SHC1 that mediates interaction with EGFR resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 pathway (By similarity). Negatively regulates platelet aggregation by decreasing platelet adhesion on type I collagen through the GPVI-FcRgamma complex (By similarity). Inhibits cell migration and cell scattering through interaction with FLNA; interfers with the interaction of FLNA with RALA (PubMed:16291724). Mediates bile acid transport activity in a phosphorylation dependent manner (By similarity). Negatively regulates osteoclastogenesis (By similarity). ; FUNCTION: Isoform 8: Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Promotes populations of T cells regulating IgA production and secretion associated with control of the commensal microbiota and resistance to enteropathogens (By similarity).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001558 regulation of cell growth
GO:0001570 vasculogenesis
GO:0001667 ameboidal-type cell migration
GO:0001818 negative regulation of cytokine production
GO:0001889 liver development
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001911 negative regulation of leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001914 regulation of T cell mediated cytotoxicity
GO:0001915 negative regulation of T cell mediated cytotoxicity
GO:0001933 negative regulation of protein phosphorylation
GO:0001974 blood vessel remodeling
GO:0002011 morphogenesis of an epithelial sheet
GO:0002040 sprouting angiogenesis
GO:0002228 natural killer cell mediated immunity
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002347 response to tumor cell
GO:0002366 leukocyte activation involved in immune response
GO:0002418 immune response to tumor cell
GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002423 natural killer cell mediated immune response to tumor cell
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002710 negative regulation of T cell mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002716 negative regulation of natural killer cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002831 regulation of response to biotic stimulus
GO:0002832 negative regulation of response to biotic stimulus
GO:0002834 regulation of response to tumor cell
GO:0002835 negative regulation of response to tumor cell
GO:0002837 regulation of immune response to tumor cell
GO:0002838 negative regulation of immune response to tumor cell
GO:0002855 regulation of natural killer cell mediated immune response to tumor cell
GO:0002856 negative regulation of natural killer cell mediated immune response to tumor cell
GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002859 negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0003158 endothelium development
GO:0006469 negative regulation of protein kinase activity
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007229 integrin-mediated signaling pathway
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0010543 regulation of platelet activation
GO:0010544 negative regulation of platelet activation
GO:0010565 regulation of cellular ketone metabolic process
GO:0010594 regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010876 lipid localization
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015721 bile acid and bile salt transport
GO:0015849 organic acid transport
GO:0015850 organic hydroxy compound transport
GO:0016049 cell growth
GO:0016053 organic acid biosynthetic process
GO:0017157 regulation of exocytosis
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022612 gland morphogenesis
GO:0030099 myeloid cell differentiation
GO:0030168 platelet activation
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030851 granulocyte differentiation
GO:0030852 regulation of granulocyte differentiation
GO:0030853 negative regulation of granulocyte differentiation
GO:0030856 regulation of epithelial cell differentiation
GO:0031341 regulation of cell killing
GO:0031342 negative regulation of cell killing
GO:0031348 negative regulation of defense response
GO:0031623 receptor internalization
GO:0032102 negative regulation of response to external stimulus
GO:0032612 interleukin-1 production
GO:0032652 regulation of interleukin-1 production
GO:0032692 negative regulation of interleukin-1 production
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033673 negative regulation of kinase activity
GO:0034103 regulation of tissue remodeling
GO:0034109 homotypic cell-cell adhesion
GO:0034110 regulation of homotypic cell-cell adhesion
GO:0034111 negative regulation of homotypic cell-cell adhesion
GO:0035726 common myeloid progenitor cell proliferation
GO:0038016 insulin receptor internalization
GO:0038127 ERBB signaling pathway
GO:0038158 granulocyte colony-stimulating factor signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042110 T cell activation
GO:0042180 cellular ketone metabolic process
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0042304 regulation of fatty acid biosynthetic process
GO:0042326 negative regulation of phosphorylation
GO:0043112 receptor metabolic process
GO:0043114 regulation of vascular permeability
GO:0043116 negative regulation of vascular permeability
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043301 negative regulation of leukocyte degranulation
GO:0043316 cytotoxic T cell degranulation
GO:0043317 regulation of cytotoxic T cell degranulation
GO:0043318 negative regulation of cytotoxic T cell degranulation
GO:0043434 response to peptide hormone
GO:0043542 endothelial cell migration
GO:0044283 small molecule biosynthetic process
GO:0044319 wound healing, spreading of cells
GO:0045055 regulated exocytosis
GO:0045088 regulation of innate immune response
GO:0045446 endothelial cell differentiation
GO:0045601 regulation of endothelial cell differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045717 negative regulation of fatty acid biosynthetic process
GO:0045765 regulation of angiogenesis
GO:0045824 negative regulation of innate immune response
GO:0045833 negative regulation of lipid metabolic process
GO:0045920 negative regulation of exocytosis
GO:0045922 negative regulation of fatty acid metabolic process
GO:0045953 negative regulation of natural killer cell mediated cytotoxicity
GO:0046394 carboxylic acid biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0046942 carboxylic acid transport
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048514 blood vessel morphogenesis
GO:0048732 gland development
GO:0048771 tissue remodeling
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050777 negative regulation of immune response
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050854 regulation of antigen receptor-mediated signaling pathway
GO:0050856 regulation of T cell receptor signaling pathway
GO:0050858 negative regulation of antigen receptor-mediated signaling pathway
GO:0050860 negative regulation of T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051055 negative regulation of lipid biosynthetic process
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051348 negative regulation of transferase activity
GO:0060312 regulation of blood vessel remodeling
GO:0060627 regulation of vesicle-mediated transport
GO:0061008 hepaticobiliary system development
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070527 platelet aggregation
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071593 lymphocyte aggregation
GO:0072330 monocarboxylic acid biosynthetic process
GO:0072574 hepatocyte proliferation
GO:0072575 epithelial cell proliferation involved in liver morphogenesis
GO:0072576 liver morphogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090330 regulation of platelet aggregation
GO:0090331 negative regulation of platelet aggregation
GO:0090504 epiboly
GO:0090505 epiboly involved in wound healing
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1901142 insulin metabolic process
GO:1901143 insulin catabolic process
GO:1901184 regulation of ERBB signaling pathway
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903305 regulation of regulated secretory pathway
GO:1903306 negative regulation of regulated secretory pathway
GO:1903385 regulation of homophilic cell adhesion
GO:1903531 negative regulation of secretion by cell
GO:1903670 regulation of sprouting angiogenesis
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1904018 positive regulation of vasculature development
GO:2000027 regulation of organ morphogenesis
GO:2000345 regulation of hepatocyte proliferation
GO:2000346 negative regulation of hepatocyte proliferation
GO:2001212 regulation of vasculogenesis
GO:2001214 positive regulation of vasculogenesis
Molecular Function GO:0003779 actin binding
GO:0005319 lipid transporter activity
GO:0005342 organic acid transmembrane transporter activity
GO:0008028 monocarboxylic acid transmembrane transporter activity
GO:0015125 bile acid transmembrane transporter activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0031005 filamin binding
GO:0046943 carboxylic acid transmembrane transporter activity
GO:1901618 organic hydroxy compound transmembrane transporter activity
GO:1990782 protein tyrosine kinase binding
Cellular Component GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0016328 lateral plasma membrane
GO:0030133 transport vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0042101 T cell receptor complex
GO:0043235 receptor complex
GO:0045177 apical part of cell
GO:0045178 basal part of cell
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1474244: Extracellular matrix organization
R-HSA-1566977: Fibronectin matrix formation
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CEACAM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CEACAM1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25744717MelanomaPromote immunity (NK cell function)CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
25744717MelanomaInhibit immunity (NK cell function)Conversely, CEACAM1-4L downregulated cell surface levels of the NKG2D ligands MICA and ULBP2 by enhanced shedding, thereby promoting malignant character.
25363763Colorectal CarcinomaInhibit immunity (T cell function)Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models.
22466331MelanomaInhibit immunity; immunotherapy targetWe have previously identified CEACAM1 as a tumor escape mechanism from cytotoxic lymphocytes. Here, we present substantial evidence in vitro and in vivo that blocking of CEACAM1 function with a novel monoclonal antibody (MRG1) is a promising strategy for cancer immunotherapy.
22143889Melanoma; Colon CarcinomaInhibit immunityCEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. We show that tumor cell-associated CEACAM1 causes intracellular retention of various NKG2D ligands in mouse and human tumor cells. CEACAM1-silenced tumor cells expressed more cell surface NKG2D ligands and exhibited greater sensitivity to natural killer cell-mediated cytolysis in vitro and rejection in vivo.
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CEACAM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CEACAM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.8310.00542
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.380.504
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.1640.151
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2970.539
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0070.997
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6740.773
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3710.551
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8420.584
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1390.934
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.470.0989
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0630.0906
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2160.226
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CEACAM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEACAM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEACAM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEACAM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEACAM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CEACAM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CEACAM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCEACAM1
Namecarcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
Aliases BGP1; CD66a; BGPI; CD66a antigen; antigen CD66; CD antigen CD66a; BGP-1; Biliary glycoprotein 1; Carcinoembr ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CEACAM1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CEACAM1.
ID Name Drug Type Targets #Targets
DB00113Technetium Tc-99m arcitumomabBiotechCEACAM11